Apotransferrin in Combination with Ciprofloxacin Slows Bacterial Replication, Prevents Resistance Amplification, and Increases Antimicrobial Regimen Effect

Author:

Ambrose Paul G.12,VanScoy Brian D.1,Luna Brian M.34ORCID,Yan Jun34,Ulhaq Amber34,Nielsen Travis B.34,Rudin Sue56,Hujer Kristine56,Bonomo Robert A.567,Actis Luis7ORCID,Skaar Eric8,Spellberg Brad3

Affiliation:

1. Institute for Clinical Pharmacodynamics, Schenectady, New York, USA

2. University of Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York, USA

3. Department of Medicine, Keck School of Medicine at the University of Southern California, Los Angeles, California, USA

4. Department of Molecular Microbiology and Immunology, Keck School of Medicine at the University of Southern California, Los Angeles, California, USA

5. Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA

6. Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA

7. Departments of Pharmacology, Molecular Biology and Microbiology, Biochemistry, and Proteomics and Bioinformatics, Case Western Reserve University, Cleveland, Ohio, USA

8. Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee, USA

Abstract

There has been renewed interest in combining traditional small-molecule antimicrobial agents with nontraditional therapies to potentiate antimicrobial effects. Apotransferrin, which decreases iron availability to microbes, is one such approach.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference20 articles.

1. World Health Organization. 30 April 2014. Antimicrobial resistance: global report on surveillance. WHO, Geneva, Switzerland. https://www.who.int/drugresistance/documents/surveillancereport/en/.

2. World Health Organization. 27 March 2015. Antimicrobial resistance: draft global action plan on antimicrobial resistance. WHO, Geneva, Switzerland. http://www.wpro.who.int/entity/drug_resistance/resources/global_action_plan_eng.pdf .

3. Food and Drug Administration. 2018. Food and Drug Administration workshop. Development of non-traditional therapies for bacterial infections. 21 and 22 August 2018. https://www.fda.gov/Drugs/NewsEvents/ucm606052.htm.

4. ESCMID. 2017. ASM/ESCMID Conference on Drug Development To Meet the Challenge of Antimicrobial Resistance. Lisbon, Portugal, 4 to 7 September 2018. https://www.ecmm.info/news/escmidasm-conference-drug-development-meet-challenge-antimicrobial-resistance-4-7-september-2018-lisbon-portugal/.

5. Bacterial Replication Rate Modulation in Combination with Antimicrobial Therapy: Turning the Microbe against Itself

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3